Janssen-Cilag International NV, a Johnson & Johnson company, announced that the CHMP of the European Medicines Agency has recommended the approval of a new indication for DARZALEX, or daratumumab, subcutaneous formulation as monotherapy for the treatment of adult patients with smouldering multiple myeloma at high-risk of developing multiple myeloma. The CHMP recommendation is supported by data from the Phase 3 AQUILA study.
Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine, said: "Pending European Commission approval, patients and physicians will have an option to treat high-risk smouldering multiple myeloma, with the aim to intercept this complex blood cancer before it develops into active disease and importantly, before end-organ damage occurs."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.